A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
Where this comes from
- Record sourced from PubMed, PMID 24065317.
- Also identified by DOI 10.1093/cid/cit653.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3-coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a shorter course of peg-IFN/RBV therapy may be sufficient in this population.
Medical subject headings
- Antiviral Agents
- HIV Infections
- Hepacivirus
- Hepatitis C, Chronic
- Interferon-alpha
- Polyethylene Glycols
- Ribavirin
- Viral Load